- Country: Cyprus
Entities › name
Hims Hers
17 headlines · 4 outlets · 2026-10-12 → 2026-11-10 · Wikipedia ↗ · 🔒 Follow
Latest coverage
- Country: United States
Hims & Hers teases November launch of Peptides+
- Country: Cyprus
Canaccord reiterates Hims & Hers stock rating after Q3 results
- Country: United States
Hims & Hers anticipates Q4 revenue of $875M-$895M while preparing broader GLP-1 assortment and international marketing push
- Country: Cyprus
Hims & Hers to offer unapproved peptides after US eases curbs
- Country: Cyprus
Earnings call transcript: Hims & Hers misses Q3 2026 profit view, shares fall
- Country: Cyprus
Hims & Hers earnings up next: Can GLP-1 boom drive profit?
- Country: Cyprus
Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Country: United States
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
- Country: United States